Status:
RECRUITING
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Conditions:
High Grade Serous Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high...
Detailed Description
After being informed about the study and potential risks, all patient giving wirtting informed consent. During surgery, tissue and blood samples will be conserved for the study. In this study will be...
Eligibility Criteria
Inclusion
- Patient aged \>18
- Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
- Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
- Patient who has given informed, written and express consent,
- Patient affiliated with a French health insurance scheme.
Exclusion
- Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
- Patient who will not have surgery
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Patient under guardianship, curatorship or safeguarding of justice,
- Pregnant and/or nursing patient,
- Patient with a history of other cancers within 5 years/10 years prior to inclusion
Key Trial Info
Start Date :
December 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06084195
Start Date
December 19 2023
End Date
October 1 2029
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NOUGARET Stephanie
Montpellier, France, 34298